Bio-Path Holdings Inc. (NASDAQ: BPTH) Stock Information | RedChip

Bio-Path Holdings Inc. (NASDAQ: BPTH)


$1.2200
-0.2700 ( -12.23% ) 2.9M

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Market Data


Open


$1.2200

Previous close


$1.4900

Volume


2.9M

Market cap


$5.94M

Day range


$1.0400 - $1.4450

52 week range


$0.5933 - $12.0000

SEC Filings


Form Type Description Pages Date
8-k 8K-related 15 Apr 15, 2024
8-k 8K-related 16 Apr 04, 2024
8-k 8K-related 15 Apr 02, 2024
8-k 8K-related 16 Mar 27, 2024
8-k 8K-related 16 Mar 26, 2024
8-k 8K-related 14 Mar 13, 2024
8-k 8K-related 14 Mar 11, 2024
8-k 8K-related 16 Mar 08, 2024
10-k Annual reports 85 Mar 07, 2024
8-k 8K-related 17 Feb 23, 2024

Latest News